弥漫性大B细胞淋巴瘤(DLBCL)是一种最常见的非霍奇金淋巴瘤，诊断病例在美国约占淋巴瘤的30%。它是一种特异质性疾病。由于临床多样性和复杂性,又有新的突变在某些难治性患者身上被发现。阿斯利康需要创建一种弥漫性巨大B细胞淋巴瘤的合适的临床模型。
具体链接在：https://www.innocentive.com/ar/challenge/9933016
AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL)
TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP
AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL.
This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery).
The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.
[更多]
